Hospital Universitario Nuestra Seora de Candelaria

Unidad de Investigacin
Publicaciones

Selección de publicaciones de entre 50 en los 6 últimos años:
*CA: Corresponding author

  • Snchez-Nio MD, Bozic M, Crdoba-Lans E, Valcheva P, Gracia O, Fernndez E, Navarro-Gonzlez JF*, Ortiz A*, Valdvielso JM*. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. American Journal of Physiology - Renal Physiology 2012;302:F647-657. *Senior authorships
  • Luis-Rodrguez D, Martnez-Castelao A, Grriz JL, De Alvaro F, Navarro-Gonzlez JF*. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World Journal of Diabetes 2012;15:3:7-18.
  • Donate-Correa J, Muros-de-Fuentes M, Mora-Fernndez C, Navarro-Gonzlez JF*. FGF23-Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine & Growth Factor Reviews 2012;23:37-46.
  • Maca M, Del Castillo N, Navarro-Gonzlez JF*. The renin-angiotensin-aldosterone system in renal and cardiovascular disease and the effect of its pharmacological blockade. Journal of Diabetes and Metabolism 2012;3:171.
  • Aguilar C, Hernndez-Daz I, Lorenzo-Daz F, Navarro JF, Hughes TE, Giraldez T, Alvarez de la Rosa D. Identification of permissive insertion sites for generating functional fluorescent mineralocorticoid receptors. Endocrinology 2012;153:3517-3525.
  • Del Castillo N, Garca-Garca P, Rivero A, Jimnez-Sosa A, Maca M, Getino MA, Mndez ML, Garca-Prez J, Navarro-Gonzlez JF*. Should we adjust erythropoiesis-stimulating agent dosage to post-dialysis hemoglobin levels? A pilot study. BMC Nephrology 2012;13:60.
  • Martnez-Castelao A, Grriz JL, Sola E, Morillas C, Jover A, Coronel F, Navarro-Gonzlez JF, De Alvaro F. A propsito de las discrepancias entre documentos de consenso, guas de prctica clnica y normativa legal en el tratamiento de la diabetes tipo 2. Nefrologa 2012;32:419-426.
  • Mndez-lvarez S, Pulido-Reyes G, Donate-Correa J, Soriano Bentez de Lugo A. Molecular Microbial Diagnostic in Lung Transplant Recipients. Journal of Cancer Therapy, 2012;3: 511-520
  • Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García J.
    Inflammatory pathways in the pathogenesis of diabetic nephropathy.
    Nature Review Nephrology 2011; 7: 327-340. FI : 4.750
  • Navarro González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J.
    Effect of phosphate binders on serum inflammatory profile, soluble cd14 and endotoxin levels in hemodialysis patients.
    Clinical Journal of the American Society of Nephrology 2011; 6: 2272-2279. FI: 4.763
  • Navarro-González JF, Mora-Fernández C, Muros M, Herrera H, Meneses  B, García J.
    Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.
    Journal of Diabetes and its Complications, 2011; 25: 314-319.  FI: 2.147
  • Martínez-Castelao A, Górriz JL, Portolés JM, de Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Trocca JJ, Natarajan A, Batlle D.
    Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study.
    BMC Nephrology 2011;12:53. FI: 2.140
  • Casanova C, De Pablos JP, Navarro J, Aguirre-Jaime A, Toledo P, Córdoba E, Baz R, Celli BR.
    Microalbuminuria and hypoxemia in patients with COPD.
    American Journal of Respiratory and Critical Care Medicine 2010;182:1004-1010. FI: 10.191
  • García-García P, Rivero A, del Castillo N, Jarque A, Getino MA, García-Pérez J, Navarro-González JF.
    Infectious spondilodyscitis in hemodialysis.
    Seminars in Dialysis 2010; 23: 619-626. FI: 3.366
  • Navarro-González JF*, Mora-Fernández C, Gómez-Chinchón M, Muros M, Herrera H, García J.
    Serum and gene expression profile of Tumor Necrosis Factor-alfa and Interleukin-6 in hypertensive diabetic patients. Effect of amlodipine administration.
    International Journal of Immunopathology and Pharmacology 2010;23: 51-59.  FI: 2.793